KALA BIO, Inc.

KALA

NASDAQ

Healthcare

Biotechnology

Arlington, MA, US38 employeeskalarx.com

$0.17

+0.01(4.11%)

52W $0.16 – $19.63

AI-generated

Kala Bio, Inc.

$4MMkt Cap

$790.9KRev TTM

-$112MNI TTM

-0.0xP/E TTM

What Changed Recently

Material Agreement

Mar 3, 2026

, the Company relied upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Regu

View filing →

Management Change

Feb 19, 2026

. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. On February 16, 2026, David Lazar notified KALA BIO, I

View filing →

Management Change

Feb 4, 2026

. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. On February 2, 2026, David Lazar tendered his resignat

View filing →

View all recent events →

Fundamentals

How The Business Makes Money

Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

Industry Biotechnology

Analyst View

Peer Companies

Company	Price	Change	Market Cap	P/E
SNGXSoligenix, Inc.	$1.14	-0.87%	$11M	-0.5
VYNEVYNE Therapeutics Inc.	$0.61	+0.58%	$10M	-1.0
IBOImpact BioMedical Inc.	$0.60	-1.55%	$8M	—
KTTAPasithea Therapeutics Cor...	$0.77	+3.49%	$6M	-0.4
OGENOragenics, Inc.	$0.58	+4.91%	$3M	—
AIMAIM ImmunoTech Inc.	$0.60	+9.05%	$2M	—
CANFCan-Fite BioPharma Ltd.	$3.10	+0.49%	$2M	—
ENSCEnsysce Biosciences, Inc.	$0.60	+9.45%	$2M	-0.2

Company Profile

CIK0001479419

ISINUS4831192020

CUSIP483119103

Phone781 996 5252

Address1167 Massachusetts Avenue, Arlington, MA, 02476, US

SEC EDGAR